{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:31:51Z","timestamp":1759336311107,"version":"3.44.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejphar.2022.174862","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T01:55:07Z","timestamp":1646618107000},"page":"174862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine\/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use"],"prefix":"10.1016","volume":"921","author":[{"given":"Dilek","family":"Kaya-Aky\u00fczl\u00fc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"\u00d6zkan-Kotilo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-075X","authenticated-orcid":false,"given":"\u015eafak","family":"Yal\u00e7\u0131n-\u015eahiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"A\u011fta\u015f-Ertan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-5739","authenticated-orcid":false,"given":"\u0130nci","family":"\u00d6zg\u00fcr-\u0130lhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.174862_bib1","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1172\/JCI70395","article-title":"Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression","volume":"123","author":"Anderson","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.174862_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/molbev\/msp276","article-title":"Multiple functional variants in cis modulate PDYN expression","volume":"27","author":"Babbitt","year":"2010","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.ejphar.2022.174862_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3565(25)10296-6","article-title":"Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats","volume":"264","author":"Bals-Kubik","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174862_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archpsyc.55.11.982","article-title":"Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism","volume":"55","author":"Bierut","year":"1998","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.ejphar.2022.174862_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/mp.2011.124","article-title":"ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry","volume":"17","author":"Bierut","year":"2012","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.psyneuen.2007.12.010","article-title":"Control of hormonal stress reactivity by the endogenous opioid system","volume":"33","author":"Bilkei-Gorzo","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2022.174862_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fpsyt.2019.00626","article-title":"Molecular imaging of opioid and dopamine systems: insights into the pharmacogenetics of opioid use disorders","volume":"10","author":"Burns","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"Kappa-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction","volume":"35","author":"Butelman","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2022.174862_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5455\/bcp.20150404070711","article-title":"Reliability and validity of the Turkish version of the clinical opiate withdrawal scale (COWS)","volume":"25","author":"Canan","year":"2015","journal-title":"Bull. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2022.174862_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.112.083337","article-title":"Dynorphin--still an extraordinarily potent opioid peptide","volume":"83","author":"Chavkin","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molbrainres.2005.07.008","article-title":"Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males","volume":"140","author":"Cheng","year":"2005","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2022.174862_bib14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/hmg\/ddm140","article-title":"In vitro assays fail to predict in vivo effects of regulatory polymorphisms","volume":"16","author":"Cirulli","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2022.174862_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1369-1600.2009.00151.x","article-title":"An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population","volume":"14","author":"Clarke","year":"2009","journal-title":"Addiction Biol."},{"key":"10.1016\/j.ejphar.2022.174862_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/299079a0","article-title":"Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor","volume":"299","author":"Corbett","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.174862_bib17","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1017\/S0033291721000969","article-title":"Genetics of substance use disorders: a review","volume":"51","author":"Deak","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ejphar.2022.174862_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1139\/jpn.0605","article-title":"Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence","volume":"31","author":"Dean","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ejphar.2022.174862_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effect of opioids: action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2022.174862_bib20","first-page":"4","article-title":"Investigation of the relationship between PDYN gene polymorphisms and tendency to heroin use","volume":"1","author":"Esfahani","year":"2020","journal-title":"Personalized Med. J."},{"key":"10.1016\/j.ejphar.2022.174862_bib21","first-page":"70","article-title":"Reliability and validity of the Penn Alcohol Craving Scale (PACS) Revised Version for substance craving in male substance dependent inpatients","volume":"22","author":"Evren","year":"2011","journal-title":"Turk. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib23","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.03.008","article-title":"Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: an ecological momentary assessment study","volume":"187","author":"Fatseas","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2022.174862_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0269881110367724","article-title":"Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala","volume":"25","author":"Femen\u00eda","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biopsycho.2011.06.007","article-title":"Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene","volume":"88","author":"Flory","year":"2011","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.ejphar.2022.174862_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrg1635","article-title":"The genetics of addictions: uncovering the genes","volume":"6","author":"Goldman","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2022.174862_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.neuron.2012.12.034","article-title":"Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity","volume":"77","author":"Graziane","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2022.174862_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1521-0391.2012.12008.x","article-title":"Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence","volume":"22","author":"Gros","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.ejphar.2022.174862_bib31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.addbeh.2009.03.010","article-title":"Understanding comorbidity between substance use, anxiety and affective disorders: broadening the research base","volume":"34","author":"Hall","year":"2009","journal-title":"Addict. Behav."},{"key":"10.1016\/j.ejphar.2022.174862_bib32","first-page":"1","article-title":"Evaluation of prodynorphin gene polymorphisms and their association with heroin addiction in a sample of the southeast Iranian population","volume":"7","author":"Hashemi","year":"2018","journal-title":"Mol. Biol. Res. Commun."},{"key":"10.1016\/j.ejphar.2022.174862_bib33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1017\/S0033291797005643","article-title":"Genetic and environmental contributions to alcohol dependence","volume":"27","author":"Heath","year":"1997","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ejphar.2022.174862_bib84","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1542\/peds.2006-0223","article-title":"Age of Alcohol-Dependence Onset: Associations With Severity of Dependence and Seeking Treatment","volume":"118","author":"Hingson","year":"2006","journal-title":"PEDIATRICS"},{"key":"10.1016\/j.ejphar.2022.174862_bib34","first-page":"3","article-title":"Reliability and validity of Beck Depression Inventory among university students","volume":"7","author":"Hisli","year":"1989","journal-title":"T\u00fcrk Psikol. Derg."},{"key":"10.1016\/j.ejphar.2022.174862_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brainres.2010.07.022","article-title":"Influence of brain-derived neurotrophic factor (Val66Met) genetic polymorphism on the ages of onset for heroin abuse in males","volume":"1353","author":"Hou","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2022.174862_bib36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/FPC.0b013e32834a53f9","article-title":"COMT gene haplotype associated with methamphetamine abuse","volume":"21","author":"Jugurnauth","year":"2011","journal-title":"Pharmacogenetics Genom."},{"issue":"8","key":"10.1016\/j.ejphar.2022.174862_bib37","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.175.4.351","article-title":"Genetic and environmental risk factors in the aetiology of illicit drug initiation and subsequent misuse in women","volume":"175","author":"Kendler","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.174862_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2022.174862_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuropharm.2013.05.024","article-title":"Addiction as a stress surfeit disorder","volume":"76 Pt B","author":"Koob","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1176\/appi.ajp.2016.16010078","article-title":"An opioid for depression?","volume":"173","author":"Kosten","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib42","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/sj.npp.1300959","article-title":"Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice","volume":"31","author":"Kuzmin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study","volume":"76","author":"Latif","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","article-title":"Buprenorphine has potent kappa opioid receptor antagonist activity","volume":"26","author":"Leander","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib46","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1038\/npp.2014.126","article-title":"Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence","volume":"39","author":"Lutz","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2022.174862_bib48","article-title":"Bidirectional relationship between heroin addiction and depression: behavioural and neural studies","author":"Moustafa","year":"2020","journal-title":"Curr. Psychol."},{"key":"10.1016\/j.ejphar.2022.174862_bib49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2022.174862_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","article-title":"The association between naltrexone treatment and symptoms of depression in opioid-dependent patients","volume":"37","author":"Mysels","year":"2011","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.ejphar.2022.174862_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0024-3205(92)90077-3","article-title":"Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and dynorphin concentrations","volume":"51","author":"Nabeshima","year":"1992","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.174862_bib52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","article-title":"Delta opioid antagonist effects of buprenorphine in rhesus monkeys","volume":"13","author":"Negus","year":"2002","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib53","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.0710902105","article-title":"Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression","volume":"105","author":"Nikoshkov","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2022.174862_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2006.02.038","article-title":"Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence","volume":"400","author":"Nomura","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2022.174862_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/ijamh-2013-0069","article-title":"Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature","volume":"25","author":"Norelli","year":"2013","journal-title":"Int. J. Adolesc. Med. Health"},{"key":"10.1016\/j.ejphar.2022.174862_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addbeh.2014.09.021","article-title":"Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model","volume":"41","author":"Northrup","year":"2015","journal-title":"Addict. Behav."},{"key":"10.1016\/j.ejphar.2022.174862_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2022.174862_bib58","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2022.174862_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12888-016-1191-0","article-title":"Age of onset of substance use and psychosocial problems among individuals with substance use disorders","volume":"17","author":"Poudel","year":"2017","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1515\/nsad-2015-0048","article-title":"Rusmisbruk, angst og depresjon etter 10 \u00e5r: en prospektiv unders\u00f8kelse av stoffmisbrukere med og uten LAR-behandling","volume":"32","author":"Ravndal","year":"2017","journal-title":"Nord. Stud. Alcohol Drugs"},{"key":"10.1016\/j.ejphar.2022.174862_bib61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00041444-200512000-00013","article-title":"A functional prodynorphin promoter polymorphism and opioid dependence","volume":"15","author":"Ray","year":"2005","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.ejphar.2022.174862_bib62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(25)33306-9","article-title":"Buprenorphine: differential interaction with opiate receptor subtypes in vivo","volume":"223","author":"Sad\u00e9e","year":"1982","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174862_bib63","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.psychres.2014.06.048","article-title":"Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence","volume":"219","author":"Saify","year":"2014","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2022.174862_bib64","first-page":"371","article-title":"Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and methamphetamine dependence. Open access maced","volume":"3","author":"Saify","year":"2014","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.ejphar.2022.174862_bib65","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/j.1360-0443.2009.02648.x","article-title":"Timing of first alcohol use and alcohol dependence: evidence of common genetic influences","volume":"104","author":"Sartor","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.ejphar.2022.174862_bib66","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.2015.15101354","article-title":"Opioids in psychiatric disorders: back to the future?","volume":"173","author":"Schatzberg","year":"2015","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib67","first-page":"263","article-title":"A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder","volume":"4","author":"Segui","year":"2020","journal-title":"J. Transl. Genet. Genom"},{"key":"10.1016\/j.ejphar.2022.174862_bib68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-3565(25)38109-7","article-title":"Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors","volume":"265","author":"Shippenberg","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174862_bib69","first-page":"163","article-title":"Turkish version of the Beck Anxiety Inventory: psychometric properties","volume":"12","author":"Ulusoy","year":"1998","journal-title":"J. Cognit. Psychother."},{"key":"10.1016\/j.ejphar.2022.174862_bib70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/(SICI)1096-8628(19970725)74:4<439::AID-AJMG16>3.0.CO;2-J","article-title":"High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers","volume":"74","author":"Vandenbergh","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejphar.2022.174862_bib71","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1017\/S0033291714002165","article-title":"The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies","volume":"45","author":"Verhulst","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ejphar.2022.174862_bib72","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2011.02.010","article-title":"Association between heroin dependence and prodynorphin gene polymorphisms","volume":"85","author":"Wei","year":"2011","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2022.174862_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2001.tb03556.x","article-title":"Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors","volume":"937","author":"Weiss","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2022.174862_bib74","first-page":"496","article-title":"Prodynorphin gene promoter repeat associated with cocaine\/alcohol codependence. Addict","volume":"12","author":"Williams","year":"2007","journal-title":"Biol."},{"key":"10.1016\/j.ejphar.2022.174862_bib75","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/npp.2008.142","article-title":"Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone","volume":"34","author":"Wittmann","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2022.174862_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3565(24)37186-1","article-title":"Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study","volume":"284","author":"Xi","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.174862_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","article-title":"Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial","volume":"173","author":"Yovell","year":"2015","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.174862_bib78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neulet.2018.08.023","article-title":"Genetic association analyses and meta-analysis of Dynorphin-Kappa Opioid system potential functional variants with heroin dependence","volume":"685","author":"Yuanyuan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2022.174862_bib79","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/NDT.S159954","article-title":"Gender-specific association of functional prodynorphin 68 bp repeats with cannabis exposure in an African American cohort","volume":"14","author":"Yuferov","year":"2018","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2022.174862_bib80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2019.03.038","article-title":"Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: effect on age trajectory of heroin use","volume":"704","author":"Yuferov","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2022.174862_bib81","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00213-015-3891-4","article-title":"Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients","volume":"232","author":"Zaaijer","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2022.174862_bib82","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/syn.21638","article-title":"Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats","volume":"67","author":"Zhou","year":"2013","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2022.174862_bib83","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1471-4159.2000.740472.x","article-title":"An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression","volume":"74","author":"Zimprich","year":"2000","journal-title":"J. Neurochem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:00:28Z","timestamp":1757977228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922001236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":83,"alternative-id":["S0014299922001236"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174862","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine\/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174862"}}